Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 14/20 | 0.58 |
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5268593 | 0.85 | GPR119 (0.65) | GPR119KDM1AUSP30ALDH1A1 | |
| SCHEMBL951540 | 0.84 | GPR119 (0.67) | GPR119USP30ALDH1A1 | |
| SCHEMBL4504506 | 0.82 | EPHX2 (0.41) | GPR119 | |
| SCHEMBL3605978 | 0.81 | GPR119 (0.69) | GPR119KDM1A | |
| SCHEMBL30876497 | 0.81 | GPR119 (0.57) | GPR119KDM1AUSP30 | |
| SCHEMBL22387771 | 0.81 | GPR119 (0.60) | GPR119KDM1AUSP30 | |
| SCHEMBL1809399 | 0.81 | GPR119 (0.57) | GPR119KDM1AUSP30 | |
| SCHEMBL693678 | 0.81 | GPR119 (0.55) | GPR119 | |
| SCHEMBL29796027 | 0.80 | KDM1A (0.58) | GPR119KDM1AUSP30 | |
| SCHEMBL6481542 | 0.80 | GPR119 (0.62) | GPR119KDM1AUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242656-A1 | N-Substituted-N-Sulfonylaminocyclopropane Compounds and Pharmaceutical Use Thereof | JAPAN TOBACCO INC. | 2008-10-02 | — | — | US | disclosed |
| US-20050222146-A1 | N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242656-A1 | N-Substituted-N-Sulfonylaminocyclopropane Compounds and Pharmaceutical Use Thereof | MMP13, MMP11, MMP3 | GPR119 783/4885KDM1A 512/4885USP30 2655/4885 |
| US-20050222146-A1 | N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof | MMP13, MMP11, MMP1 | GPR119 784/4885KDM1A 477/4885USP30 2747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.